265 related articles for article (PubMed ID: 20482685)
1. The hand-foot-syndrome associated with medical tumor therapy - classification and management.
Degen A; Alter M; Schenck F; Satzger I; Völker B; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2010 Sep; 8(9):652-61. PubMed ID: 20482685
[TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
[TBL] [Abstract][Full Text] [Related]
3. Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
Wolber C; Udvardi A; Tatzreiter G; Schneeberger A; Volc-Platzer B
J Dtsch Dermatol Ges; 2009 May; 7(5):449-52. PubMed ID: 19178612
[TBL] [Abstract][Full Text] [Related]
4. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Lipworth AD; Robert C; Zhu AX
Oncology; 2009; 77(5):257-71. PubMed ID: 19923864
[TBL] [Abstract][Full Text] [Related]
5. [Dermatologic toxicity to sorafenib].
Velázquez D; de la Cueva P; Zamberk P; Lázaro P
Actas Dermosifiliogr; 2009; 100(6):518-20. PubMed ID: 19709563
[No Abstract] [Full Text] [Related]
6. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).
Anderson R; Jatoi A; Robert C; Wood LS; Keating KN; Lacouture ME
Oncologist; 2009 Mar; 14(3):291-302. PubMed ID: 19276294
[TBL] [Abstract][Full Text] [Related]
7. Severe sorafenib-induced hand-foot skin reaction.
Cuesta L; Betlloch I; Toledo F; Latorre N; Monteagudo A
Dermatol Online J; 2011 May; 17(5):14. PubMed ID: 21635836
[TBL] [Abstract][Full Text] [Related]
8. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Bednaríková D; Kocák I
Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib-associated hand-foot syndrome in Japanese patients.
Iijima M; Fukino K; Adachi M; Tsukamoto T; Murai M; Naito S; Minami H; Furuse J; Akaza H
J Dermatol; 2011 Mar; 38(3):261-6. PubMed ID: 21342228
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
11. The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy.
Janusch M; Fischer M; Marsch WCh; Holzhausen HJ; Kegel T; Helmbold P
Eur J Dermatol; 2006; 16(5):494-9. PubMed ID: 17101468
[TBL] [Abstract][Full Text] [Related]
12. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
14. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.
Nagore E; Insa A; Sanmartín O
Am J Clin Dermatol; 2000; 1(4):225-34. PubMed ID: 11702367
[TBL] [Abstract][Full Text] [Related]
15. [Hand-foot syndrome and sorafenib].
Milano G; Mortier L; Digue L; Desmedt E; Ravaud A
Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
[TBL] [Abstract][Full Text] [Related]
16. [Palmoplantar cutaneous reaction to sorafenib].
Echeverría B; Llombart B; Botella-Estrada R; Guillén C
Actas Dermosifiliogr; 2009 Oct; 100(8):736-7. PubMed ID: 19775561
[No Abstract] [Full Text] [Related]
17. Interstitial granulomatous drug reaction to sorafenib.
Martínez-Morán C; Nájera L; Ruiz-Casado AI; Romero-Maté A; Espinosa P; Meseguer-Yebra C; Córdoba S; Borbujo JM
Arch Dermatol; 2011 Sep; 147(9):1118-9. PubMed ID: 21931061
[No Abstract] [Full Text] [Related]
18. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
[TBL] [Abstract][Full Text] [Related]
19. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
Webster-Gandy JD; How C; Harrold K
Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
